CR Intrinsic Investors LLC, et al., Charged $276 Million in Scheme Involving Alzheimer's Drug (Largest Insider Trading Case by SEC)

The SEC charged the hedge fund advisory firm CR Intrinsic Investors LLC, its former portfolio manager, and a medical consultant for an expert network firm for their roles in a $276 million insider trading scheme involving a clinical trial for an Alzheimer's drug being jointly developed by two pharmaceutical companies. According to the SEC, the gains alleged to have been generated in this scheme make it the largest insider trading case ever charged by the SEC.

View complaint in full here (links externally to SEC website).See also: Press Release; SEC Director Khuzami's Remarks